{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027667","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-08-13T20:07:45+00:00","discovered_at":"2026-08-13T20:10:02.663337+00:00","generated_at":"2026-08-13T20:10:24.535192+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmuCell Q2 2026 net income $1.8M, revenue up 11.5% to $7.2M","bullets":["Net income $1.8M ($0.20 diluted EPS) vs $0.5M ($0.06) in Q2 2025; adjusted EBITDA $2.7M vs $1.4M.","Product sales $7.2M, +11.5% YoY; gross margin fell to 33.9% from 43.7% on lower volumes and quality scrap.","Received $2M legal settlement from former Re-Tain contract manufacturer, boosting net income.","Cash rose to $8.9M from $3.8M at year-end; working capital $16.6M, equity $31.4M.","Plans ~$3.5M freeze-drying capacity (H1 2027) and ~$4.5M liquid processing expansion; aims to triple capacity in 18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027667","json":"https://secwatch.observer/filing/0001437749-26-027667.json","markdown":"https://secwatch.observer/filing/0001437749-26-027667.md","text":"https://secwatch.observer/filing/0001437749-26-027667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926027667/0001437749-26-027667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926027667/iccc20260808_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:10:24.535192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}